Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Yantai New Drug Creation Shandong Laboratory have reported new degrader-antibody-drug conjugates (DACs) potentially useful for the treatment of cancer which are comprised of an antibody covalently bound to a molecular glue degrader moiety.

Beijing Tide Pharmaceutical Co. Ltd. has divulged new salts of known angiotensin AT2 recpetor antagonists potentially useful for the treatment of allergy, autoimmune and demyelinating diseases, cerebrovascular, respiratory, cognitive, gastrointestinal and inflammatory disorders, among others.

Inxmed (Nanjing) Co. Ltd. has discovered new focal adhesion kinase (FAK) and focal adhesion kinase 2 (FADK2; PTK2B; PYK2) dual inhibitors potentially useful for the treatment of cancer.

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of rheumatoid arthritis, amyotrophic lateral sclerosis, frontotemporal dementia, multiple sclerosis, prion disease, stroke, Parkinson’s and Alzheimer’s disease.

Zhejiang Normal University has patented new inhibitors of proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutants potentially useful for the treatment of cancer.

Prelude Therapeutics Inc. has identified new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)- and SMARCA4-targeting moiety.

Kimia Therapeutics Inc. has disclosed new ATP-dependent RNA helicase A (DHX9) inhibitors potentially useful for the treatment of cancer, autoimmune and viral infections.

A Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. patent describes new complement factor B (CFB) inhibitors potentially useful for the treatment of IgA nephropathy, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, age-related macular degeneration, cardiovascular disorder and cancer.

Shanghai Meiyue Biotech Development Co. Ltd. has synthesized new benzopyrimidine compounds acting as histone-lysine N-methyltransferase EHMT2 (H3-K9-HMTase 3; G9a) inhibitors potentially useful for the treatment of cancer, autoimmune disease, metabolic diseases, gastrointestinal and inflammatory disorders.

Iksuda Therapeutics Ltd. and UCL Business Ltd. have prepared new antibody-drug conjugates comprising antibodies targeting B7 homolog 3 (B7-H3, CD276) covalently linked to cytotoxic drug, designed for potential use in the treatment of cancer.